GILEAD SCIENCES SL
🇪🇸Spain
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 98
- Registration Number
- NCT02397694
Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 33
- Registration Number
- NCT02397707
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇳🇿Auckland Clinical Studies, Auckland, New Zealand
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 33
- Registration Number
- NCT02392611
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 128
- Registration Number
- NCT02378961
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Borland-Groover Clinic, Jacksonville, Florida, United States
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 205
- Registration Number
- NCT02378935
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Southwest Care Center, Santa Fe, New Mexico, United States
GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT02377336
Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 13
- Registration Number
- NCT02365506
- Locations
- 🇺🇸
University of Rochester Medical Center/Strong Memorial Hospital, Rochester, New York, United States
Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT02365532
- Locations
- 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 17
- Registration Number
- NCT02350569
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 111
- Registration Number
- NCT02346721
© Copyright 2024. All Rights Reserved by MedPath